<DOC>
	<DOCNO>NCT02325219</DOCNO>
	<brief_summary>The purpose study demonstrate superiority CNTO 1959 ( guselkumab ) placebo treatment participant moderate severe plaque-type psoriasis ( A common genetically determine , chronic , inflammatory skin disease characterize rounded erythematous , dry , scale patch ) .</brief_summary>
	<brief_title>An Efficacy Safety CNTO 1959 ( Guselkumab ) Participants With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>A Phase 3 , multicenter ( one hospital medical school team work medical research study ) , randomize ( study drug assign chance ) , double-blind ( neither Investigator participant know study treatment ) , placebo-controlled ( pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study CNTO 1959 ( Guselkumab ) treatment participant moderate severe plaque-type psoriasis . Participants receive either treatment CNTO 1959 ( guselkumab ) 50 milligram ( mg ) 100 mg Placebo 50 mg 100 mg . Participants primarily assess Investigator 's Global Assessment ( IGA ) Score Psoriasis Area Severity Index ( PASI ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis without psoriatic arthritis least 6 month Screening Have PASI great equal ( &gt; = ) 12 Screening Baseline Have IGA &gt; = 3 Screening Baseline Have involve body surface area ( BSA ) &gt; =10 percent ( % ) Screening Baseline Be candidate phototherapy systemic treatment psoriasis ( either naive history previous treatment ) Has history current sign symptom severe , progressive , uncontrolled cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance Has unstable cardiovascular disease , define recent clinical deterioration ( example , unstable angina , atrial fibrillation ) last 3 month cardiac hospitalization within last 3 month Screening Currently malignancy history malignancy within 5 year screen ( exception nonmelanoma skin cancer adequately treat evidence recurrence least 3 month first study drug administration cervical carcinoma situ treat evidence recurrence least 3 month Screening Has history lymphoproliferative disease , include lymphoma ; history monoclonal gammopathy undetermined significance ( MGUS ) ; sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy and/or splenomegaly Has history chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection ( eg , bronchiectasis ) , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , fungal infection ( mucocutaneous candidiasis ) , open , drain , infected skin wound ulcer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>Guselkumab</keyword>
	<keyword>Placebo</keyword>
</DOC>